T1	PrimaryOutcome 48 76	time to clinical improvement
T2	OutcomeDefinition 93 275	time from randomization to an improvement of two points (from the status at randomization) on a seven-category ordinal scale or live discharge from the hospital, whichever came first
R1	DefinedAs Arg1:T1 Arg2:T2	
T3	OtherOutcome 1058 1073	clinical status
T4	OutcomeDefinition 1077 1123	assessed with the seven-category ordinal scale
T5	TimeFrame 1124 1140	on days 7 and 14
T6	OtherOutcome 1142 1151	mortality
T7	TimeFrame 1152 1161	at day 28
T8	OtherOutcome 1167 1201	duration of mechanical ventilation
T9	OtherOutcome 1207 1247	duration of hospitalization in survivors
T10	OtherOutcome 1257 1306	time (in days) from treatment initiation to death
R2	DefinedAs Arg1:T3 Arg2:T4	
R3	MeasuredAt Arg1:T3 Arg2:T5	
R4	MeasuredAt Arg1:T6 Arg2:T7	
T11	OtherOutcome 1340 1386	proportions with viral RNA detection over time
T12	OtherOutcome 1391 1433	viral RNA titer area-under-the-curve (AUC)
T13	OtherOutcome 1474 1488	adverse events
T14	OtherOutcome 1521 1543	serious adverse events
T15	OtherOutcome 1549 1587	premature discontinuation of treatment
T16	OutcomeDefinition 1609 1722	classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0
R5	DefinedAs Arg1:T13 Arg2:T16	
